Comparison of the bronchodilator effect of inhaled short- and long-acting β2-agonists in children with bronchial asthma. A randomised trial

Clinical Drug Investigation

Volumn 16, Issue 1, 1998, Pages 19-24

  Verini, Marcello ^a,b   Verrotti, Alberto ^a   Greco, Rita ^a   Chiarelli, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Ospedale Policlinico Colle dell' Ara   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; PROCATEROL; SALBUTAMOL; SALMETEROL;

ADOLESCENT; ARTICLE; ASTHMA; BRONCHODILATATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY FLOW; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION;

EID: 0031927225     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816010-00003     Document Type: Article

References (20)

1. Arvidsson P, Larsson S, Lofdahl CG, et al. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168-73
2. Becker AB, Simons FE, Formoterol. a new, long-acting selective beta 2-adrenergic receptor agonist double-blind comparison with salbutamol) and placebo in children with asthma. J Allergy Clin Immunol 1989; 84: 891-5
3. Bentur L, Kerem E, Canny G, et al. Response of acute asthma to a beta 2 agonist in children less than two years of age. Ann Allergy 1990; 65: 122-6
4. Boner AI, Spezia E, Piovesan P, et al. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 1994; 149: 935-9
5. 2-adrenergic agonist. Respir Med 1990; 84: 293-5
6. Verberne AAPH, de Jongste JC. The role of inhaled long-acting bronchodilator therapy. Eur Respir Rev 1996; 6: 199-203
7. Graff-Lonnevig V. Browaldh L. Twelve hours bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol. Clin Exp Allergy 1990; 20: 429-32
8. Lebecque P, Vliers S, De Saint Moulin T, et al. The effect of a single dose of formoterol using an aerosol inhaler in asthmatic children. A randomized. controlled, double-blind study. Rev Mal Respir 1994; 11: 47-50
9. Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-agonist, decreases airway responsiveness in children with asthma. Lung 1990; 168 Suppl.: 99-102
10. Foucard T, Lonnerholm G. A study with cumulative doses of formoterol and salbutamol in children with asthma. Eur Respir J 1991; 4: 1174-7
11. 2-agonist. inhaled twice daily, in stable asthmatic subjects. Chest 1992; 101: 1019-22
12. 2-agonist. in chronic obstructive airway disease. Lung 1990; 168 Suppl.: 83-9
13. Anderson GP. Pharmacology of formoterol: an innovative bronchodilator. Agents Actions 1991; 34 Suppl.: 97-115
14. Anderson GP, Linden A, Rabe KF. Why are long-acting betaadrenoceptor agonists long-acting? Eur Respir J 1994: 7: 569-78
15. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991: 42: 115-37
16. Lofdahl CG. Svedmyr N. Beta-agonists - friends or foes [editorial]. Eur Respir J 1991; 4: 1161-5
17. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formotertol. a potent and long acting sympathomimetic. Thoras 1992; 47: 30-3
18. Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol 1992; 89: 1176-82
19. Palmqvist M, Balder B, Lowhagen O, et al. Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting β2-agonist. J Allergy Clin Immunol 1992; 89: 844-9
20. Ramsdale EH, Otis J, Kline PA, et al. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled β2-agonist formoterol. Am Rev Respir Dis 1991; 143: 998-1001